跳至主要内容
临床试验/ACTRN12620001256965
ACTRN12620001256965进行中(未招募)2 期

Chronic Myocardial Injury-Evaluating The Possible Role Of SGLT-2 Inhibition. A phase II multicentre double blind randomised parallel group comparison of 10mg dapagliflozin versus placebo over 6 months in chronic myocardial injury

Flinders University of South Australia0 个研究点目标入组 30 人开始时间: 2020年11月24日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients will be considered eligible if they meet all of the following:
  • 1. Chronic elevation of defined as a troponin T velocity of <3ng/L/hour assessed with at least 3 troponin values measued, with at least 2 of these being 4 hours apart, AND with at least 1 of these values >14ng/L, within the first 24 hours of initial presentation;
  • 2. Age of 18 years or older;
  • 3. Willing to give informed consent

排除标准

  • Patients will be considered ineligible if they meet any of the following:
  • 1.Troponin T: Maximal in hospital troponin level >100ng/L within the first 24 hours of initial presentation or acute myocardial injury, defined as a rise and/or fall in troponin T with a velocity of >3ng/L/hr;
  • 2.Recent coronary revascularization (PCI and CABG) within the last 6 months
  • 3.Active heart failure with clinical symptoms of dyspnoea or extra-vascular volume overload and a NT-proBNP level >500ng/L;
  • 4.Treated diabetes, defined as receiving any long-term/chronic oral or parenteral pharmacotherapies for the treatment of established diabetes;
  • 5.Renal impairment with a documented eGFR of <45ml/min/1.73m2;
  • 6.Documented HBA1C level >7% in the previous 3 months;
  • 7.Presentation with documented ST segment elevation on ECG representing either ST-segment elevation MI or pericarditis;
  • 8.Documented pulmonary embolus or aortic dissection;
  • 9.History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time;
  • 10.Recurrent genital infections;
  • 11.Pregnancy or breast-feeding (female), planning to donate sperm (male) or trying to conceive within the next 6 months (males and females);
  • 12.History of allergy to SGLT2 inhibitors or similar drug
  • 13.Concurrent participation in another randomized clinical trial;
  • 14.Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site)
  • 15.Previous enrolment or randomisation in the present study
  • 16.Currently taking an SGLT2 inhibitor or previous treatment with SGLT2 inhibitor in the last 6 months

研究者

发起方
Flinders University of South Australia

相似试验